Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer

25 Nov 2020

Abstract excerpt

mutation. Theoretically, PARP inhibitors (PARPi) eliminate tumor cells by disrupting DNA damage repair through either PARylation or the homologous recombination (HR) pathway. However, resistance to PARPi greatly hinders therapeutic effectiveness in triple-negative breast cancer (TNBC). Owing to the high heterogeneity and few genetic targets in TNBC, there has been limited therapeutic progress in the past decades....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33324554
DOI: 10.3389/fonc.2020.578095

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast CancerPMID 33324554Read ↗

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Semantic proximity Read ↗

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and ResistanceSemantic proximity Read ↗

BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.Semantic proximity Read ↗

PARP inhibitor resistance: the underlying mechanisms and clinical implicationsSemantic proximity Read ↗

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitorsSemantic proximity Read ↗

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic ApproachesSemantic proximity Read ↗

PARP Inhibitors in Breast and Ovarian CancerSemantic proximity Read ↗

Facing inevitable PARPis resistance: Mechanisms and therapeutic strategies for breast cancer treatmentSemantic proximity Read ↗

PARP Inhibitors Resistance: Mechanisms and PerspectivesSemantic proximity Read ↗

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancersSemantic proximity Read ↗

PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments.Semantic proximity Read ↗

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.